title: Compared effects of isoxicam and indomethacin on the urinary excretion of prostaglandins in degenerative articular diseases.
abstract: The effects of a 7 day-treatment with isoxicam (200 mg/24 h) on the urinary excretion of prostaglandins (PG) were compared to those of indomethacin (150 mg/24 h) in a double-blind randomized study conducted in 18 patients with degenerative arthritic disease and normal renal function. Indomethacin decreased the urinary excretion of PGF2 alpha by about 70% and 6-keto-PGF1 alpha and thromboxane (Tx)B2, the stable break-down products of prostacyclin and TxA2 respectively, by about 40%. Isoxicam effects on urinary PG did not significantly differ from those of indomethacin. During both treatments, urinary gamma-glutamyl transferase and N- acetyl-glucosaminidase remained stable and none of the changes in the urinary excretion of PGs could be related to either plasma or urinary drug concentrations. In conclusion, chronic administration of isoxicam inhibited the renal PG biosynthesis to a similar extent than indomethacin which suggests that non steroidal anti-inflammatory drugs of the oxicam group ought also be used cautiously in patients with renal impairment.
authors.affiliation: Department of Physiology and Clinical Pharmacology, UA CNRS 606, Faculty of Pharmacy, Lyon, France.
authors.forename: J
authors.initials: J
authors.lastname: Sassard
authors.forename: J
authors.initials: J
authors.lastname: Geoffroy
authors.forename: N
authors.initials: N
authors.lastname: Ferry
authors.forename: D
authors.initials: D
authors.lastname: Benzoni
authors.forename: M
authors.initials: M
authors.lastname: Mathieu
authors.forename: E
authors.initials: E
authors.lastname: Lejeune
authors.forename: G
authors.initials: G
authors.lastname: Llorca
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy* / Q000652:urine; D015237:Dinoprost / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011453:Prostaglandins / Q000652:urine*; D013929:Thromboxane B2 / Q000652:urine
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011453:Prostaglandins; D010894:Piroxicam; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C013580:isoxicam; D015237:Dinoprost; D007213:Indomethacin